Hematopoietic Recovery and Priming — Therapeutic Effects of GM-CSF in the Treatment of AML

  • T. Büchner
  • W. Hiddemann
  • B. Wörmann
  • R. Rottmann
  • G. Maschmeyer
  • W.-D Ludwig
  • M. Zühlsdorf
  • K. Buntkirchen
  • A. Sander
  • J. Aswald
  • I. Binder
  • S. Prisett
  • M. C. Sauerland
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 37)

Summary

After a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceeding chemotherapy and continuing until neutrophil recovery in the initial 5 chemotherapy courses for patients with newly diagnosed AML. The CR rate in patients of 16–75 (median 50) years is 79% in GM-CSF patients and 82% in controls. GM-CSF patients showed a trend to more frequent rapid blast clearance and fewer persistent leukemias and — in patients under age 60 — a significantly superior remission duration as of this update. It should be shown later by this study whether GM-CSF multiple course priming and longterm administration adds to the cure rate of patients with AML.

Keywords

Placebo Toxicity Leukemia Neutropenia Cytosine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Büchner Th, Hiddemann W, Koenigsmann M et al. (1991) Recombinant granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: 1190–1197PubMedGoogle Scholar
  2. 2.
    Ohno R, Tomonaga M, Kobayashi T et al. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323: 871–877PubMedCrossRefGoogle Scholar
  3. 3.
    Rowe JM, Andersen J, Mazza JJ et al. (1993) Phase III randomized placebo-controlled study of granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients (55–70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (ECOG). Blood 82 (1): 1299Google Scholar
  4. 4.
    Stone R, George S, Berg D et al. (1994) GM-CSF ‘V’ placebo during remission induction for patients > 60 years old with de novo acute myeloid leukemia: CALGB study #8923. Proc ASCO 13: 992Google Scholar
  5. 5.
    Griffin JD, Young D, Herrmann F et al. (1986) Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic Leukemia. Blood, 67: 1448–1453PubMedGoogle Scholar
  6. 6.
    Miyauchi J, Kelleher CA, Yang Y et al. (1987) The effect of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 70: 657–663PubMedGoogle Scholar
  7. 7.
    Kelleher C, Miyauchi J, Wong G et al. (1987) Synergism between recombinant growth factors GM-CSF and G-CSF, acting on the blast cells of acute myeloblastic leukemia. Blood 69: 1489–1503Google Scholar
  8. 8.
    Vellenga E, Young DC, Wagner K et al. (1987) The effect of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 69: 1771–1776PubMedGoogle Scholar
  9. 9.
    Cannistra SA, Groshek P, Griffin JD (1989) Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 3: 328–334PubMedGoogle Scholar
  10. 10.
    Bettelheim P, Valent P, Andreeff M et al. (1991) Recombinant human granulocyte-macrophage colony-stimulating factor in de novo acute myeloid leukemia, Blood 77: 700–711PubMedGoogle Scholar
  11. 11.
    Reuter CH, Auf der Landwehr U, Schleyer E et al. (1994) Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte macrophage colony stimulating factor. Leukemia 8: 217–225.PubMedGoogle Scholar
  12. 12.
    Koistinen P, Wang C, Curtis JE et al. (1991) Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity. Leukemia 5: 789–795PubMedGoogle Scholar
  13. 13.
    Estey EH, Thall PF, Kantarjian H et al. (1992) Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood 79: 2246–2255PubMedGoogle Scholar
  14. 14.
    Lotem J, Sachs L (1992) Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80:1750–1757PubMedGoogle Scholar
  15. 15.
    Bhalla K, Tang C, Ibrado AM et al. (1992) Granulocyte-macrophage colony-stimulating-factor/interleukin-3 fusion protein (pIXY 321) enhances high-dose ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells. Blood 80: 2883–2890PubMedGoogle Scholar
  16. 16.
    Büchner Th, Urbanitz D, Hiddemann W et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589PubMedGoogle Scholar
  17. 17.
    Hiddemann W, Kreutzmann H, Straif K et al. (1987) High-dose cytosine-arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 69: 744–749PubMedGoogle Scholar
  18. 18.
    Büchner T, Hiddemann W, Löffler G et al. (1991) Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: Data from the AML Cooperative Group. Sem Hematol 28 (4): 76–79Google Scholar
  19. 19.
    Büchner T, Hiddemann W, Koenigsmann M et al. (1991) Recombinant human granulocyte-macro phage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: 1190–1197PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • T. Büchner
    • 1
  • W. Hiddemann
    • 1
  • B. Wörmann
    • 1
  • R. Rottmann
    • 1
  • G. Maschmeyer
    • 1
  • W.-D Ludwig
    • 1
  • M. Zühlsdorf
    • 1
  • K. Buntkirchen
    • 1
  • A. Sander
    • 1
  • J. Aswald
    • 1
  • I. Binder
    • 1
  • S. Prisett
    • 1
  • M. C. Sauerland
    • 1
  1. 1.Department of Medicine, Hematology/OncologyUniversity of MünsterGermany

Personalised recommendations